ENLV vs. SEEL, VIRX, ASMB, ANEB, GRTX, NCNA, ADAG, SYRS, BLPH, and CNTB
Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Seelos Therapeutics (SEEL), Viracta Therapeutics (VIRX), Assembly Biosciences (ASMB), Anebulo Pharmaceuticals (ANEB), Galera Therapeutics (GRTX), NuCana (NCNA), Adagene (ADAG), Syros Pharmaceuticals (SYRS), Bellerophon Therapeutics (BLPH), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical preparations" industry.
Enlivex Therapeutics vs.
Enlivex Therapeutics (NASDAQ:ENLV) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Seelos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Enlivex Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Seelos Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500.
Seelos Therapeutics received 24 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 77.59% of users gave Enlivex Therapeutics an outperform vote while only 69.70% of users gave Seelos Therapeutics an outperform vote.
1.8% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 25.4% of Seelos Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 5.1% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Enlivex Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 309.84%. Given Enlivex Therapeutics' higher probable upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Seelos Therapeutics.
In the previous week, Enlivex Therapeutics and Enlivex Therapeutics both had 1 articles in the media. Enlivex Therapeutics' average media sentiment score of 1.66 beat Seelos Therapeutics' score of 0.40 indicating that Enlivex Therapeutics is being referred to more favorably in the media.
Enlivex Therapeutics' return on equity of -38.86% beat Seelos Therapeutics' return on equity.
Summary
Enlivex Therapeutics beats Seelos Therapeutics on 7 of the 12 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enlivex Therapeutics Competitors List
